Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients

Go back to Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients